Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vesselle, H.
Right arrow Articles by Wood, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vesselle, H.
Right arrow Articles by Wood, D. E.
Clinical Cancer Research Vol. 8, 3315-3323, November 2002
© 2002 American Association for Cancer Research

Clinical Trials

In Vivo Validation of 3'deoxy-3'-[18F]fluorothymidine ([18F]FLT) as a Proliferation Imaging Tracer in Humans

Correlation of [18F]FLT Uptake by Positron Emission Tomography with Ki-67 Immunohistochemistry and Flow Cytometry in Human Lung Tumors1

Hubert Vesselle2, John Grierson, Mark Muzi, Jeffrey M. Pugsley, Rodney A. Schmidt, Peter Rabinowitz, Lanell M. Peterson, Eric Vallières and Douglas E. Wood

Departments of Radiology (Division of Nuclear Medicine) [H. V., J. G., M. M., J. M. P., L. M. P.], Pathology [R. A. S., P. R.], and Surgery (Division of Thoracic Surgery) [E. V., D. E. W.], University of Washington, Seattle, Washington 98195

Purpose: Tumor proliferation has prognostic value in resectedearly stage non-small cell lung cancer (NSCLC) and can, therefore, predict which NSCLCs are at high risk for recurrence after resection and would benefit from additional therapy. It may also predict which tumor will respond to cell cycle-targeted chemotherapy and help assess the tumor response, besides helping to differentiate benign from malignant lung lesions. We evaluated whether the uptake of the new positron emission tomography (PET) tracer 3'deoxy-3'-[18F]fluorothymidine (FLT) in a series of suspected NSCLCs correlated with tumor proliferation assessed by Ki-67 immunohistochemistry and flow cytometry.

Experimental Design: Ten patients with 11 biopsy-proven or clinically suspected NSCLC underwent 2-h dynamic PET imaging after i.v. injection of 0.07 mCi/kg FLT. Tumor FLT uptake was quantitated with the maximum pixel standardized uptake value (maxSUV), the partial volume corrected maxSUV (PV-corr-maxSUV), the average SUV over a small region-of-interest (aveSUV) and with Patlak analysis of FLT flux (aveFLTflux). The lesion diameter from computed tomography was used to correct the maxSUV for PV effects using recovery coefficients determined for the General Electric Advance PET scanner. Two of the 11 lesions were benign inflammatory lesions and 9 were NSCLCs. Immunohistochemistry for Ki-67 (proliferation index marker) was performed on all 11 tissue specimens (10 resections, 1 NSCLC percutaneous biopsy), and the S-phase fraction (SPF) from flow cytometry could be determined for 10. The specimens were reviewed for histology and cellular differentiation (poor, moderate, well). Lesions ranged from 1.6 to 7.7 cm.

Results: Excellent correlations were found between SUV measures of FLT uptake and Ki-67 scores [percentage of positive cells; maxSUV versus Ki-67: Rho = 0.78, P = 0.0043 (n = 11); PV-corr-maxSUV versus Ki-67: Rho = 0.83, P = 0.0028 (n = 10); aveSUV versus Ki-67: Rho = 0.84, P = 0.0011 (n = 11)]. Correlation between Ki-67 proliferation scores and Patlak measures of FLT uptake were also strong: aveFLTflux versus Ki-67: Rho = 0.94, P < 0.0001 (n = 11). The correlation between the SPF and all indices of FLT uptake was weaker and reached statistical significance for only two uptake indices [maxSUV versus SPF: Rho = 0.69, P = 0.03 (n = 10); PV-corr-maxSUV versus SPF: Rho = 0.36, P = 0.35 (n = 9); aveSUV versus SPF: Rho = 0.67, P = 0.03 (n = 10); aveFLTflux versus SPF: Rho = 0.46, P = 0.18 (n = 10)].

Conclusion: FLT PET may be used to noninvasively assess proliferation rates of lung masses in vivo. Therefore, FLT PET may play a significant role in the evaluation of indeterminate pulmonary lesions, in the prognostic assessment of resectable NSCLC, and possibly in the evaluation of NSCLC response to chemotherapy.




This article has been cited by other articles:


Home page
 JNMHome page
K. Herrmann, F. Eckel, S. Schmidt, K. Scheidhauer, B. J. Krause, J. Kleeff, T. Schuster, H.-J. Wester, H. Friess, R. M. Schmid, et al.
In Vivo Characterization of Proliferation for Discriminating Cancer from Pancreatic Pseudotumors
J. Nucl. Med., September 1, 2008; 49(9): 1437 - 1444.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. von Forstner, J.-H. Egberts, O. Ammerpohl, D. Niedzielska, R. Buchert, P. Mikecz, U. Schumacher, K. Peldschus, G. Adam, C. Pilarsky, et al.
Gene Expression Patterns and Tumor Uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an Orthotopic Mouse Xenotransplantation Model of Pancreatic Cancer
J. Nucl. Med., August 1, 2008; 49(8): 1362 - 1370.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. R. Bading and A. F. Shields
Imaging of Cell Proliferation: Status and Prospects
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 64S - 80S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Ullrich, H. Backes, H. Li, L. Kracht, H. Miletic, K. Kesper, B. Neumaier, W.-D. Heiss, K. Wienhard, and A. H. Jacobs
Glioma Proliferation as Assessed by 3'-Fluoro-3'-Deoxy-L-Thymidine Positron Emission Tomography in Patients with Newly Diagnosed High-Grade Glioma
Clin. Cancer Res., April 1, 2008; 14(7): 2049 - 2055.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. Tian, X. Yang, L. Yu, P. Chen, J. Xin, L. Ma, H. Feng, Y. Tan, Z. Zhao, and W. Wu
A Multicenter Clinical Trial on the Diagnostic Value of Dual-Tracer PET/CT in Pulmonary Lesions Using 3'-Deoxy-3'-18F-Fluorothymidine and 18F-FDG
J. Nucl. Med., February 1, 2008; 49(2): 186 - 194.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir
Molecular Imaging Techniques in Body Imaging
Radiology, November 1, 2007; 245(2): 333 - 356.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Chen, S. Delaloye, D. H.S. Silverman, C. Geist, J. Czernin, J. Sayre, N. Satyamurthy, W. Pope, A. Lai, M. E. Phelps, et al.
Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study
J. Clin. Oncol., October 20, 2007; 25(30): 4714 - 4721.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. Chen
Clinical Applications of PET in Brain Tumors
J. Nucl. Med., September 1, 2007; 48(9): 1468 - 1481.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Vesselle, J. D. Freeman, L. Wiens, J. Stern, H. Q. Nguyen, S. E. Hawes, P. Bastian, A. Salskov, E. Vallieres, and D. E. Wood
Fluorodeoxyglucose Uptake of Primary Non-Small Cell Lung Cancer at Positron Emission Tomography: New Contrary Data on Prognostic Role
Clin. Cancer Res., June 1, 2007; 13(11): 3255 - 3263.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
E. G.C. Troost, W. V. Vogel, M. A.W. Merkx, P. J. Slootweg, H. A.M. Marres, W. J.M. Peeters, J. Bussink, A. J. van der Kogel, W. J.G. Oyen, and J. H.A.M. Kaanders
18F-FLT PET Does Not Discriminate Between Reactive and Metastatic Lymph Nodes in Primary Head and Neck Cancer Patients
J. Nucl. Med., May 1, 2007; 48(5): 726 - 735.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. B. Been, A. J.H. Suurmeijer, P. H. Elsinga, P. L. Jager, R. J. van Ginkel, and H. J. Hoekstra
18F-Fluorodeoxythymidine PET for Evaluating the Response to Hyperthermic Isolated Limb Perfusion for Locally Advanced Soft-Tissue Sarcomas
J. Nucl. Med., March 1, 2007; 48(3): 367 - 372.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
T. M. Blodgett, C. C. Meltzer, and D. W. Townsend
PET/CT: Form and Function
Radiology, February 1, 2007; 242(2): 360 - 385.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. K. Buck, M. Bommer, S. Stilgenbauer, M. Juweid, G. Glatting, H. Schirrmeister, T. Mattfeldt, D. Tepsic, D. Bunjes, F. M. Mottaghy, et al.
Molecular Imaging of Proliferation in Malignant Lymphoma.
Cancer Res., November 15, 2006; 66(22): 11055 - 11061.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Muzi, A. M. Spence, F. O'Sullivan, D. A. Mankoff, J. M. Wells, J. R. Grierson, J. M. Link, and K. A. Krohn
Kinetic Analysis of 3'-Deoxy-3'-18F-Fluorothymidine in Patients with Gliomas
J. Nucl. Med., October 1, 2006; 47(10): 1612 - 1621.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Leyton, J. P. Alao, M. Da Costa, A. V. Stavropoulou, J. R. Latigo, M. Perumal, R. Pillai, Q. He, P. Atadja, E. W.-F. Lam, et al.
In vivo Biological Activity of the Histone Deacetylase Inhibitor LAQ824 Is detectable with 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography.
Cancer Res., August 1, 2006; 66(15): 7621 - 7629.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Apisarnthanarax, M. M. Alauddin, F. Mourtada, H. Ariga, U. Raju, O. Mawlawi, D. Han, W. G. Bornmann, J. A. Ajani, L. Milas, et al.
Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3'-Deoxy-3'-3H-Fluorothymidine Using Preclinical Tumor Models
Clin. Cancer Res., August 1, 2006; 12(15): 4590 - 4597.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. A. Weber
Positron Emission Tomography As an Imaging Biomarker
J. Clin. Oncol., July 10, 2006; 24(20): 3282 - 3292.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. S. Yap, J. Czernin, M. C. Fishbein, R. B. Cameron, C. Schiepers, M. E. Phelps, and W. A. Weber
Evaluation of Thoracic Tumors With 18F-Fluorothymidine and 18F- Fluorodeoxyglucose-Positron Emission Tomography.
Chest, February 1, 2006; 129(2): 393 - 401.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. R. Tseng, M. Dandekar, M. Subbarayan, Z. Cheng, J. M. Park, S. Louie, and S. S. Gambhir
Reproducibility of 3'-Deoxy-3'-18F-Fluorothymidine MicroPET Studies in Tumor Xenografts in Mice
J. Nucl. Med., November 1, 2005; 46(11): 1851 - 1857.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. M. Kenny, D. M. Vigushin, A. Al-Nahhas, S. Osman, S. K. Luthra, S. Shousha, R. C. Coombes, and E. O. Aboagye
Quantification of Cellular Proliferation in Tumor and Normal Tissues of Patients with Breast Cancer by [18F]Fluorothymidine-Positron Emission Tomography Imaging: Evaluation of Analytical Methods
Cancer Res., November 1, 2005; 65(21): 10104 - 10112.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. Chen, T. Cloughesy, N. Kamdar, N. Satyamurthy, M. Bergsneider, L. Liau, P. Mischel, J. Czernin, M. E. Phelps, and D. H.S. Silverman
Imaging Proliferation in Brain Tumors with 18F-FLT PET: Comparison with 18F-FDG
J. Nucl. Med., June 1, 2005; 46(6): 945 - 952.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Muzi, H. Vesselle, J. R. Grierson, D. A. Mankoff, R. A. Schmidt, L. Peterson, J. M. Wells, and K. A. Krohn
Kinetic Analysis of 3'-Deoxy-3'-Fluorothymidine PET Studies: Validation Studies in Patients with Lung Cancer
J. Nucl. Med., February 1, 2005; 46(2): 274 - 282.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Waldherr, I. K. Mellinghoff, C. Tran, B. S. Halpern, N. Rozengurt, A. Safaei, W. A. Weber, D. Stout, N. Satyamurthy, J. Barrio, et al.
Monitoring Antiproliferative Responses to Kinase Inhibitor Therapy in Mice with 3'-Deoxy-3'-18F-Fluorothymidine PET
J. Nucl. Med., January 1, 2005; 46(1): 114 - 120.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. C. Detterbeck, J. F. Vansteenkiste, D. E. Morris, C. A. Dooms, A. H. Khandani, and M. A. Socinski
Seeking a Home for a PET, Part 3: Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer
Chest, November 1, 2004; 126(5): 1656 - 1666.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. C.P. Cobben, P. H. Elsinga, H. J. Hoekstra, A. J.H. Suurmeijer, W. Vaalburg, B. Maas, P. L. Jager, and H. M.J. Groen
Is 18F-3'-Fluoro-3'-Deoxy-L-Thymidine Useful for the Staging and Restaging of Non-Small Cell Lung Cancer?
J. Nucl. Med., October 1, 2004; 45(10): 1677 - 1682.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Sugiyama, H. Sakahara, K. Sato, N. Harada, D. Fukumoto, T. Kakiuchi, T. Hirano, E. Kohno, and H. Tsukada
Evaluation of 3'-Deoxy-3'-18F-Fluorothymidine for Monitoring Tumor Response to Radiotherapy and Photodynamic Therapy in Mice
J. Nucl. Med., October 1, 2004; 45(10): 1754 - 1758.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Downey, T. Akhurst, M. Gonen, A. Vincent, M. S. Bains, S. Larson, and V. Rusch
Preoperative F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value Predicts Survival After Lung Cancer Resection
J. Clin. Oncol., August 15, 2004; 22(16): 3255 - 3260.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. I. Shapiro
Preclinical and Clinical Development of the Cyclin-Dependent Kinase Inhibitor Flavopiridol
Clin. Cancer Res., June 15, 2004; 10(12): 4270S - 4275S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. van Waarde, D. C.P. Cobben, A. J.H. Suurmeijer, B. Maas, W. Vaalburg, E. F.J. de Vries, P. L. Jager, H. J. Hoekstra, and P. H. Elsinga
Selectivity of 18F-FLT and 18F-FDG for Differentiating Tumor from Inflammation in a Rodent Model
J. Nucl. Med., April 1, 2004; 45(4): 695 - 700.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
N. Oyama, D. E. Ponde, C. Dence, J. Kim, Y.-C. Tai, and M. J. Welch
Monitoring of Therapy in Androgen-Dependent Prostate Tumor Model by Measuring Tumor Proliferation
J. Nucl. Med., March 1, 2004; 45(3): 519 - 525.
[Abstract] [Full Text]

Home page
 JNMHome page
D. C.P. Cobben, B. F.A.M. van der Laan, B. Maas, W. Vaalburg, A. J.H. Suurmeijer, H. J. Hoekstra, P. L. Jager, and P. H. Elsinga
18F-FLT PET for Visualization of Laryngeal Cancer: Comparison with 18F-FDG PET
J. Nucl. Med., February 1, 2004; 45(2): 226 - 231.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Barthel, E. Aboagye, and P. Price
Reply
Cancer Res., December 1, 2003; 63(23): 8560 - 8560.
[Full Text] [PDF]

Home page
 JNMHome page
S. H. Britz-Cunningham and S. J. Adelstein
Molecular Targeting with Radionuclides: State of the Science
J. Nucl. Med., December 1, 2003; 44(12): 1945 - 1961.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. C.P. Cobben, P. H. Elsinga, A. van Waarde, and P. L. Jager
Correspondence re: H. Barthel et al., 3'-Deoxy-3'-[18F]fluorothymidine as a New Marker for Monitoring Tumor Response to Antiproliferative Therapy in Vivo with Positron Emission Tomography. Cancer Res., 63: 3791-3798, 2003.
Cancer Res., December 1, 2003; 63(23): 8558 - 8559.
[Full Text] [PDF]

Home page
 GutHome page
D L Francis, A Freeman, D Visvikis, D C Costa, S K Luthra, M Novelli, I Taylor, and P J Ell
In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography
Gut, November 1, 2003; 52(11): 1602 - 1606.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. F. Shields
PET Imaging with 18F-FLT and Thymidine Analogs: Promise and Pitfalls
J. Nucl. Med., September 1, 2003; 44(9): 1432 - 1434.
[Full Text] [PDF]

Home page
 JNMHome page
H. Vesselle, J. Grierson, L. M. Peterson, M. Muzi, D. A. Mankoff, and K. A. Krohn
18F-Fluorothymidine Radiation Dosimetry in Human PET Imaging Studies
J. Nucl. Med., September 1, 2003; 44(9): 1482 - 1488.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
C. N. Coleman
Linking Radiation Oncology and Imaging through Molecular Biology (or Now That Therapy and Diagnosis Have Separated, It's Time to Get Together Again!)
Radiology, July 1, 2003; 228(1): 29 - 35.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. K. Rowinsky
Challenges of Developing Therapeutics That Target Signal Transduction in Patients With Gynecologic and Other Malignancies
J. Clin. Oncol., May 15, 2003; 21(90100): 175s - 186.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.